EURACTIV PR

An easy way of publishing your relevant EU press releases.

EMA clarifies no scientific evidence to deter use of ibuprofen to manage coronavirus symptoms

Date

18 Mar 2020

Sections

Health & Consumers

The European Medicines Agency (EMA) has published today a press release to address concerns about the use of ibuprofen and other non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19 patients.

According to the Agency, when starting treatment for fever or pain in COVID-19, patients and healthcare professionals should consider all available treatment options including paracetamol and NSAIDs. Each medicine has its own benefits and risks which are reflected in its product information and which should be considered along with EU national treatment guidelines, most of which recommend paracetamol as a first treatment option for fever or pain.

In line with EU national treatment guidelines, patients and healthcare professionals can continue using NSAIDs (like ibuprofen) as per the approved product information. Current advice includes that these medicines are used at the lowest effective dose for the shortest possible period.

The agency also highlighted that there is currently no scientific evidence establishing a link between ibuprofen and worsening of COVID‑19. EMA is monitoring the situation closely and will review any new information that becomes available on this issue in the context of the pandemic and has committed provide further information as necessary and once the PRAC review is concluded.

Medicines for Europe 

Medicines for Europe represents the generic, biosimilar and value-added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members directly employ 190,000 people at over 400 manufacturing and 126 R&D sites in Europe and invest up to 17% of their turnover in R&D investment. Medicines for Europe member companies across Europe are both increasing access to medicines and driving improved health outcomes. They play a key role in creating sustainable European healthcare systems by continuing to provide high quality, effective generic medicines, whilst also innovating to create new biosimilar medicines and bringing to market value added medicines, which deliver better health outcomes, greater efficiency and/or improved safety in the hospital setting for patients. For more information please follow us at www.medicinesforeurope.com and on Twitter @medicinesforEU. 

Medicines for Europe Communications:

Kate O Regan koregan@medicinesforeurope.com

Jobs

BRAK - Bundesrechtsanwaltskammer
Assistenz (m/w/d)
Forum CTEP GmbH
Debate Editor (f/m/d)
Intercultural Dialogue Platform
Videography & Media Intern (Paid Internship)
Intercultural Dialogue Platform
Social Media & Graphics Intern (Paid Internship)
CENTRE TECNOLÒGIC DE TELECOMUNICACIONS DE CATALUNYA - CTTC
Researcher position in Communication Technologies Division - SMARTECH Department
One Policy Place (OPP)
Policy Analyst - EU Finance Policy
INEA - Innovation and Networks Executive Agency
PROJECT OFFICER Horizon 2020 Research and Innovation - Transport
Eastern and Midland Regional Assembly
EU support officer